Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Dianne C. Whitfield filed a Form 144 notice to sell 4,071 shares of Common Stock. The shares are tied to restricted stock vesting dated 03/17/2026 and are listed with Fidelity Brokerage Services LLC as broker. The filing also discloses prior dispositions of 15,565 shares on 01/02/2026 and 4,029 shares on 03/17/2026.
Bryan Wahl filed a Form 144 to offer 4,125 shares of Common Stock. The filing links the shares to a restricted stock vesting event dated 03/17/2026 and lists Fidelity Brokerage Services LLC as the broker. The filing also shows recent activity of 4,084 shares sold on 03/17/2026 and includes adjacent amounts $283,427.93 and $283,489.63.
Bobak Azamian reports proposed sale of common stock under Rule 144. The filing lists 11,667 common shares associated with Fidelity Brokerage Services LLC on 03/18/2026. The filing also discloses a prior sale of 10,972 shares on 03/17/2026 for $761,618.09.
The securities to be sold are listed as resulting from restricted stock vesting and are labeled compensation on 03/17/2026. Timing and exact sale methods are not detailed in the excerpt.
TARS disclosed notices under Rule 144 for transactions in its common stock. The filing lists a Restricted Stock Vesting entry of 3,610 shares dated 03/17/2026 attributed to Fidelity Brokerage Services LLC as compensation. The filing also records sales by Seshadri Neervannan of 8,366 shares on 03/04/2026 and 3,125 shares on 03/17/2026, with proceeds shown alongside each sale.
TARS files a Form 144 notice to sell 2,133 shares of Common Stock following restricted stock vesting on 03/17/2026.
The filing shows the shares are tied to compensation (restricted stock vesting). The excerpt also reports that Jeffrey Farrow sold 2,111 shares on 03/17/2026. Trading venue is listed as NASDAQ.
Aziz A. Mottiwala reports an intention to sell Common stock. The filing lists 4,330 shares of Common stock to be sold in connection with restricted stock vesting tied to compensation, with the action dated 03/17/2026 and the security shown on NASDAQ.
The filing also reports 4,286 shares of Common stock sold during the prior three months, dated 03/17/2026. The entries identify a brokerage address for Fidelity Brokerage Services LLC.
TARS submitted a Form 144 notice reporting restricted stock vesting and related disposals of common shares. The filing lists 379 common shares tied to a Restricted Stock Vesting event on 03/17/2026. It also records that 375 common shares were sold during the past three months on 03/17/2026 by Elizabeth Yeu-Lin.
Tarsus Pharmaceuticals director William J. Link, PhD sold 12,500 shares of Common Stock in open-market transactions. The sales occurred on 2026-03-16 at weighted-average prices of $68.09, $69.03, and $69.75, under an automatic Rule 10b5-1 trading plan adopted on September 8, 2025. Following these trades, he continues to hold 116,332 shares directly.
Tarsus Pharmaceuticals, Inc. Chief Human Resources Officer Dianne C. Whitfield reported the settlement of vested Restricted Stock Units into common shares. On March 15, 2026, she exercised RSUs covering 23,909 underlying shares, resulting in direct ownership of 47,302 shares of common stock.
The RSUs were granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan on March 9, 2022, March 8, 2023, March 7, 2024, and March 5, 2025. Each grant vests in four equal annual installments on March 15 of consecutive years, subject to continuous service.
Tarsus Pharmaceuticals, Inc. reported that General Counsel Bryan Wahl acquired common shares through the settlement of vested restricted stock units (RSUs). On March 15, 2026, multiple RSU awards were exercised, delivering a total of 24,236 shares of common stock at an exercise price of $0.00 per share.
Following these transactions, Wahl held 76,399 shares of Tarsus common stock directly, which includes 451 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025. The RSUs were granted between 2022 and 2025 under the 2020 Stock Plan, with 25% of each grant vesting annually on March 15, subject to continued service.